Russell Investments Group, Ltd. Blueprint Medicines Corp Transaction History

Russell Investments Group, Ltd.

$66.8 Billion
Q3 2024

A detailed history of Russell Investments Group, Ltd. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 109,028 shares of BPMC stock, worth $10.4 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

109,028

Previous 56,493 92.99%

Holding current value

$10.4 Million

Previous $6.09 Million 65.57%

% of portfolio

0.02%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$84.1 - $120.5 $4.42 Million - $6.33 Million	52,535 Added 92.99%	109,028 $10.1 Million
Q2 2024 Aug 08, 2024	SELL	$85.18 - $108.78 $104,004 - $132,820	-1,221 Reduced 2.12%	56,493 $6.09 Million
Q1 2024 May 08, 2024	BUY	$73.17 - $99.79 $1.3 Million - $1.77 Million	17,712 Added 44.28%	57,714 $5.47 Million
Q4 2023 Feb 05, 2024	SELL	$43.96 - $92.84 $2.58 Million - $5.45 Million	-58,678 Reduced 59.46%	40,002 $3.69 Million
Q3 2023 Nov 13, 2023	BUY	$46.9 - $66.0 $1.28 Million - $1.8 Million	27,200 Added 38.05%	98,680 $4.96 Million
Q2 2023 Aug 10, 2023	SELL	$42.2 - $66.37 $803,741 - $1.26 Million	-19,046 Reduced 21.04%	71,480 $4.52 Million
Q1 2023 May 09, 2023	BUY	$37.97 - $50.0 $1.08 Million - $1.42 Million	28,340 Added 45.57%	90,526 $4.07 Million
Q4 2022 Feb 08, 2023	SELL	$41.06 - $66.48 $309,592 - $501,259	-7,540 Reduced 10.81%	62,186 $2.72 Million
Q3 2022 Nov 04, 2022	BUY	$49.93 - $77.7 $175,254 - $272,727	3,510 Added 5.3%	69,726 $4.59 Million
Q2 2022 Jul 29, 2022	BUY	$45.23 - $70.15 $1.49 Million - $2.31 Million	32,917 Added 98.85%	66,216 $3.34 Million
Q1 2022 May 05, 2022	SELL	$54.1 - $110.08 $601,862 - $1.22 Million	-11,125 Reduced 25.04%	33,299 $2.13 Million
Q4 2021 Jan 21, 2022	SELL	$94.25 - $115.99 $1.01 Million - $1.24 Million	-10,664 Reduced 19.36%	44,424 $4.76 Million
Q3 2021 Nov 08, 2021	SELL	$80.98 - $109.47 $407,005 - $550,196	-5,026 Reduced 8.36%	55,088 $5.66 Million
Q2 2021 Aug 04, 2021	BUY	$82.78 - $101.0 $2.22 Million - $2.71 Million	26,800 Added 80.45%	60,114 $5.28 Million
Q1 2021 May 10, 2021	SELL	$90.71 - $108.28 $249,543 - $297,878	-2,751 Reduced 7.63%	33,314 $3.24 Million
Q4 2020 Feb 08, 2021	SELL	$92.08 - $124.48 $331,488 - $448,128	-3,600 Reduced 9.08%	36,065 $4.05 Million
Q3 2020 Nov 09, 2020	BUY	$66.45 - $92.7 $221,212 - $308,598	3,329 Added 9.16%	39,665 $3.67 Million
Q2 2020 Aug 05, 2020	SELL	$57.09 - $79.27 $441,705 - $613,311	-7,737 Reduced 17.55%	36,336 $2.83 Million
Q1 2020 May 06, 2020	BUY	$48.11 - $82.22 $2,068 - $3,535	43 Added 0.1%	44,073 $2.58 Million
Q4 2019 Jan 29, 2020	BUY	$66.73 - $82.59 $986,069 - $1.22 Million	14,777 Added 50.51%	44,030 $3.53 Million
Q3 2019 Nov 01, 2019	BUY	$72.9 - $101.41 $704,286 - $979,722	9,661 Added 49.31%	29,253 $2.15 Million
Q2 2019 Aug 09, 2019	SELL	$73.54 - $97.8 $264,008 - $351,102	-3,590 Reduced 15.49%	19,592 $1.85 Million
Q4 2018 Feb 11, 2019	SELL	$45.57 - $74.26 $139,945 - $228,052	-3,071 Reduced 11.7%	23,182 $1.25 Million
Q3 2018 Oct 26, 2018	BUY	$58.91 - $78.32 $325,183 - $432,326	5,520 Added 26.62%	26,253 $2.05 Million
Q2 2018 Aug 08, 2018	SELL	$60.96 - $101.18 $228,051 - $378,514	-3,741 Reduced 15.29%	20,733 $1.32 Million
Q1 2018 May 11, 2018	BUY	$73.28 - $102.95 $526,590 - $739,798	7,186 Added 41.57%	24,474 $2.24 Million
Q4 2017 Feb 06, 2018	SELL	$62.91 - $88.32 $477,990 - $671,055	-7,598 Reduced 30.53%	17,288 $1.34 Million
Q3 2017 Nov 07, 2017	BUY	$42.37 - $69.67 $1.05 Million - $1.73 Million	24,886	24,886 $1.73 Million

Others Institutions Holding BPMC

# of Institutions

349

Shares Held

60.2M

Call Options Held

1.05M

Put Options Held

616K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.71B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.

Account

Russell Investments Group, Ltd. Blueprint Medicines Corp Transaction History